These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9389683)

  • 41. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
    Jongen-Lavrencic M; Salesse S; Delwel R; Verfaillie CM
    Leukemia; 2005 Mar; 19(3):373-80. PubMed ID: 15674360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
    Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
    J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
    Rapozzi V; Cogoi S; Xodo LE
    Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
    Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
    J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P; Lewalle P; Taj AS; Philippe M; Larondelle Y; Vaerman JL; Wildmann C; Goldman JM; Michaux JL
    Blood; 1993 Jan; 81(2):502-9. PubMed ID: 8422466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficient protection from methotrexate toxicity and selection of transduced human hematopoietic cells following gene transfer of dihydrofolate reductase mutants.
    Meisel R; Bardenheuer W; Strehblow C; Sorg UR; Elmaagacli A; Seeber S; Flasshove M; Moritz T
    Exp Hematol; 2003 Dec; 31(12):1215-22. PubMed ID: 14662327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
    Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
    Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
    Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
    Peng C; Li S
    Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
    Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
    Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
    Bedi A; Zehnbauer BA; Collector MI; Barber JP; Zicha MS; Sharkis SJ; Jones RJ
    Blood; 1993 Jun; 81(11):2898-902. PubMed ID: 8499629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
    Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
    Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
    Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
    Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
    Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.